Immunovia, Inc. Obtains a Clinical Laboratory License from the Rhode Island Department of Health, Making the IMMray™ PanCan-d Test Available in 46 U.S. States

LUND, Sweden, May 17, 2022 /PRNewswire/ The Rhode Island Department of Health has granted Immunovia, Inc., the U.S. subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), a clinical laboratory license, allowing physicians to Rhode Island order the IMMray™ PanCan-d test for their patients.

“Receive a license in Rhode Island now allows us to offer IMMray™ PanCan-d in 46 states. We anticipate more state licenses to follow, as we strive to make IMMray™ PanCan-d available to patients across United States who are at risk for pancreatic cancer,” says Jeff BorcherdingChairman and CEO of Immunovia, Inc., the US subsidiary of Immunovia AB.

For more information please contact:
Philippe Matthew
CEO and Acting President
E-mail: [email protected]

Tobias Bulow
Senior Director of Investor Relations and Corporate Communications
E-mail: [email protected]
Tel: +46 736 36 35 74

The information was submitted for publication on March 17, 2022to 08:30 CET.

About Immunovia

Immunovia AB is a diagnostics company whose vision is to revolutionize blood diagnostics and increase survival rates for cancer patients.

Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unparalleled clinical performance. Commercialization of IMMray™ PanCan-d began in August 2021 in the UNITED STATES and IMMray™ PanCan-d is offered as a laboratory-developed test (LDT) exclusively by Immunovia, Inc. For more information, see: www.immunoviainc.com.

Immunovia is collaborating and engaging with healthcare providers, leading experts and patient advocacy groups around the world to make this test available to all high-risk pancreatic cancer groups.

the UNITED STATESthe first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than $4 billion annually.

Immunovia (IMMNOV) shares are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia–inc–achieves-clinical-laboratory-licensure-from-rhode-island-dept-of-health-making-immra,c3567971

The following files are available for download:

SOURCE Immunovia AB

Comments are closed.